中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2010年
8期
614-618
,共5页
张剑%王梦筠%许立超%顾史洋%曹军宁%胡夕春%洪小南
張劍%王夢筠%許立超%顧史洋%曹軍寧%鬍夕春%洪小南
장검%왕몽균%허립초%고사양%조군저%호석춘%홍소남
弥漫大B细胞淋巴瘤%胃肿瘤%预后因素
瀰漫大B細胞淋巴瘤%胃腫瘤%預後因素
미만대B세포림파류%위종류%예후인소
Diffuse large B-cell lymphoma%Gastric neoplasms%Prognostic factors
目的 分析原发性胃弥漫大B细胞淋巴瘤(PG-DLBCL)患者的临床特征和预后影响因素,探讨PC-DLBCL的分期系统和治疗模式.方法 回顾性分析69例PG-DLBCL患者的临床资料,以无事件生存期(EFS)和总生存期(OS)为主要研究终点.结果 全组患者的1、3和5年无事件生存率分别为83.8%、71.1%和69.0%,平均EFS为91.3个月;1、3和5年总生存率分别为91.3%、80.3%和72.4%,平均OS为98.8个月.单因素分析结果显示,改良Ann Arbor分期为ⅠE或ⅡE1期、血清乳酸脱氢酶(LDH)水平正常、血红蛋白水平正常、血清白蛋白水平正常、国际预后指数(IPI)评分为0~1分、肿瘤长径<5 cm、浸润深度浅的患者EFS和OS显著延长(均P<0.05),而患者的性别、年龄、有无B症状、ECOG体力评分结果以及治疗方法与患者的预后无关(均P>0.05).Cox多因素回归分析结果显示,改良Ann Arbor分期、血清白蛋白水平是影响PG-DLBCL患者EFS和OS的独立因素.结论 PG-DLBCL的分期系统和各种治疗措施所处的地位仍存有争议,需进一步大样本的前瞻性研究以优化PG-DLBCL的治疗方案.
目的 分析原髮性胃瀰漫大B細胞淋巴瘤(PG-DLBCL)患者的臨床特徵和預後影響因素,探討PC-DLBCL的分期繫統和治療模式.方法 迴顧性分析69例PG-DLBCL患者的臨床資料,以無事件生存期(EFS)和總生存期(OS)為主要研究終點.結果 全組患者的1、3和5年無事件生存率分彆為83.8%、71.1%和69.0%,平均EFS為91.3箇月;1、3和5年總生存率分彆為91.3%、80.3%和72.4%,平均OS為98.8箇月.單因素分析結果顯示,改良Ann Arbor分期為ⅠE或ⅡE1期、血清乳痠脫氫酶(LDH)水平正常、血紅蛋白水平正常、血清白蛋白水平正常、國際預後指數(IPI)評分為0~1分、腫瘤長徑<5 cm、浸潤深度淺的患者EFS和OS顯著延長(均P<0.05),而患者的性彆、年齡、有無B癥狀、ECOG體力評分結果以及治療方法與患者的預後無關(均P>0.05).Cox多因素迴歸分析結果顯示,改良Ann Arbor分期、血清白蛋白水平是影響PG-DLBCL患者EFS和OS的獨立因素.結論 PG-DLBCL的分期繫統和各種治療措施所處的地位仍存有爭議,需進一步大樣本的前瞻性研究以優化PG-DLBCL的治療方案.
목적 분석원발성위미만대B세포림파류(PG-DLBCL)환자적림상특정화예후영향인소,탐토PC-DLBCL적분기계통화치료모식.방법 회고성분석69례PG-DLBCL환자적림상자료,이무사건생존기(EFS)화총생존기(OS)위주요연구종점.결과 전조환자적1、3화5년무사건생존솔분별위83.8%、71.1%화69.0%,평균EFS위91.3개월;1、3화5년총생존솔분별위91.3%、80.3%화72.4%,평균OS위98.8개월.단인소분석결과현시,개량Ann Arbor분기위ⅠE혹ⅡE1기、혈청유산탈경매(LDH)수평정상、혈홍단백수평정상、혈청백단백수평정상、국제예후지수(IPI)평분위0~1분、종류장경<5 cm、침윤심도천적환자EFS화OS현저연장(균P<0.05),이환자적성별、년령、유무B증상、ECOG체력평분결과이급치료방법여환자적예후무관(균P>0.05).Cox다인소회귀분석결과현시,개량Ann Arbor분기、혈청백단백수평시영향PG-DLBCL환자EFS화OS적독립인소.결론 PG-DLBCL적분기계통화각충치료조시소처적지위잉존유쟁의,수진일보대양본적전첨성연구이우화PG-DLBCL적치료방안.
Objective To analyze the clinical features and prognostic factors of primary gastric diffuse large B-cell lymphoma (PG-DLBCL) and to evaluate the staging system and treatment modality of PG-DLBCL. Methods The clinicopathological data of 69 patients with PG-DLBCL were retrospectively analyzed. Event-free survival (EFS) and overall survival (OS) were the primary endpoints. Results The EFS rates at 1,3, and 5 years were 83.8%, 71.1%, and 69.0% , respectively, with a mean EFS of 91.3 months. The 1-, 3-, and 5-year OS rates were 91.3%, 80.3%, and 72.4%, respectively, with a mean OS of 98.8 months. Univariate analysis revealed that either EFS or OS was significantly prolonged by the following factors (P <0.05): modified Ann Arbor stage ⅠE or ⅡE1 disease; normal lactate dehydrogenase(LDH) level; normal hemoglobin level; normal albumin level; International Prognostic Index ( IPI ) of 0 or 1; tumor size < 5 cm; and less depth of invasion. While gender, age, B symptoms at presentation,performance status and treatment modality were not significantly associated with the prognosis ( P > 0.05 ).Cox regression model revealed that only modified Ann Arbor stage and albumin level were independent prognostic factors for EFS and OS. Conclusion The most accurate staging system and the exact role of different therapeutic options for PG-DLBCL are still debated. Further randomized prospective studies with a large number of patients are still needed to establish an optimal management for this disease.